USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Japan’s Finance Minister Signals Alignment With BOJ as Rate Hike Speculation Grows 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
South Korea Posts Stronger-Than-Expected 1.3% Economic Growth in Q3 
RBA Signals Possible Rate Implications as Inflation Proves More Persistent 
Tech Stocks Lift S&P 500 as Fed Rate-Cut Expectations Rise 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
U.S. May Withhold $30.4 Million From Minnesota Over Improper Commercial Driver Licenses 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Apple Appoints Amar Subramanya as New Vice President of AI Amid Push to Accelerate Innovation 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
CJ Cheiljedang, South Korea’s largest food and beverage conglomerate, is set to buy Batavia Biosciences, a Dutch bio firm for $226 million or about €195 million. It was reported that the deal came not long after the company revealed its $8.5 billion growth plan for its four major business areas.
CJ Cheiljedang which is a subsidiary of CJ Group announced on Monday, Nov. 8, that it will be acquiring the said Dutch biotech company as part of its plan to broaden its presence in the contract biopharmaceutical production market.
According to The Korea Economic Daily, the company’s board of directors already gave the “go” signal for the acquisition of 75.8% share in Batavia Biosciences. It was reportedly posted in the regulatory filing that this deal is worth ₩267.7 billion or $226 million.
Moreover, CJ Cheiljedang shared it will buy 50,807 shares in the Leiden, Netherlands-headquartered biotech firm and this includes 13,007 new shares at €3,844 per share. It should be noted that the companies’ acquisition deal is still subject to approval by regulatory authorities in South Korea and the Netherlands.
Once the transactions are complete, CJ will immediately work on the expansion of its “red bio” business which refers to the line of work in the medical and pharmaceutical fields. “There’s no dominant leader in the gene therapy treatment market,” an official at CJ said in a statement. “We want to grow big in this area as soon as possible.”
Batavia Biosciences is based in the Netherlands but is has research and development (R&D) centers and sales offices in Hong Kong and Boston, U.S.A. It was founded by the researchers of Janssen Pharmaceuticals in 2010 and mainly worked on cell and gene therapies under CDMO or Contract Development and Manufacturing Organization program. It has extensive experience in virus vaccine, viral vector, monoclonal antibody, microbial vaccine, and recombinant protein development.
Finally, BioPharma reported that with its acquisition of Batavia Biosciences, it appears that CJ Group is directing its attention back to its pharmaceutical business. After unloading its healthcare unit to Kolmar Korea in 2018, CJ seems to have revived its interest in expanding in the biopharma line.
